RA CAPITAL MANAGEMENT, L.P. bought EVMN

November 7, 2025 · Form 4 insider transaction

RA CAPITAL MANAGEMENT, L.P. bought 1,517,329 shares of Evommune, Inc., a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 5 days after the transaction.

Direction
Acquired (buy-side)
Shares
1,517,329
Price
N/A
Total value
N/A
RoleDirector, 10% owner
SecurityCommon Stock
Transaction codeC: Conversion of a derivative
Transaction dateNovember 7, 2025
Filing dateNovember 12, 2025
Shares owned after1,517,329
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of Series C Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-8.518 basis and had no expiration date.; RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.; Held directly by the Fund.

View the original Form 4 on SEC EDGAR